Sermorelin vs. Tesamorelin (Egrifta): When to Pick One, When to Stack, and How to Do It Safely

What Are Sermorelin and Tesamorelin, and How Do They Work?

Both peptides mimic growth hormone-releasing hormone (GHRH), the hypothalamic signal that tells your pituitary gland to secrete growth hormone (GH). They do not inject GH directly. Instead, they preserve the pituitary's natural pulsatile release pattern, which is why they carry a different safety profile than exogenous recombinant GH.

Sermorelin: The Older GHRH Fragment

Sermorelin is a 29-amino-acid fragment of endogenous GHRH(1-44). The FDA approved it in 1997 under the brand name Geref for diagnosing GH deficiency in children, but that approval was withdrawn in 2008 when the manufacturer voluntarily discontinued the product for commercial reasons, not safety concerns. It remains available through compounding pharmacies under physician supervision, though the FDA classifies compounded sermorelin under ongoing regulatory scrutiny. [1]

At the pituitary level, sermorelin binds the GHRH receptor (GHRHR) and increases cyclic AMP, triggering GH secretion. Its short half-life of roughly 10-12 minutes means the GH pulse is brief and physiologic. [2]

Tesamorelin: The FDA-Approved GHRH Analogue

Tesamorelin (Egrifta SV, Theratechnologies) is a full-length GHRH(1-44) analogue stabilized with a trans-3-hexenoic acid group at the N-terminus. That modification extends its plasma half-life to approximately 26 minutes and makes it more resistant to dipeptidyl peptidase-IV (DPP-IV) cleavage. The FDA granted approval in November 2010 specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. [3]

The GHRH receptor binding affinity of tesamorelin is comparable to native GHRH. Phase III data from two replicate trials (LIPO-010 and LIPO-011, combined N=816) showed that 2 mg daily reduced visceral adipose tissue (VAT) by a mean of 15.2% versus placebo at 26 weeks, with IGF-1 rising to near-normal levels in the majority of treated patients. [4]

The Evidence Base: What the Trials Actually Show

Tesamorelin's Phase III Record

The clearest clinical picture belongs to tesamorelin. The key LIPO-010 trial (N=412, randomized, double-blind, placebo-controlled, 26 weeks) demonstrated statistically significant VAT reduction of approximately 15% by CT imaging (P<0.0001). Trunk fat, measured by DEXA, fell by roughly 8%. Fasting glucose and HbA1c did not differ significantly from placebo, which is relevant because GH excess can impair insulin sensitivity. [4]

A 52-week extension of that program showed that benefits were sustained with continued therapy but reversed within 12 weeks of stopping, confirming the drug's effect requires ongoing administration. [5]

The Endocrine Society's 2012 Clinical Practice Guideline on adult GH deficiency notes that GHRH analogues can normalize IGF-1 and improve body composition but advises caution because they do not address pituitary-level GH deficiency directly. [6]

Sermorelin's Evidence Base

Sermorelin's trial history is older and thinner by modern standards. A 1996 study published in the Journal of Clinical Endocrinology and Metabolism (N=226, randomized, double-blind) showed that nightly sermorelin 0.03 mg/kg increased IGF-1 levels and reduced fat mass in older men, but the effect size was modest and the study predates current body-composition imaging standards. [7]

No head-to-head RCT comparing sermorelin to tesamorelin has been published as of mid-2025. Practitioners who prescribe sermorelin off-label for adult GH optimization rely primarily on its mechanism-of-action, the older endocrinology literature, and clinical observation. That is an evidence gap worth stating plainly.

Can You Stack Sermorelin With Tesamorelin?

Short answer: you can, but there is no published RCT showing that the combination outperforms either agent alone, and mechanistic reasoning suggests the marginal benefit may be small.

Why the Stack Is Theoretically Redundant

Both peptides bind the same receptor: GHRHR. Receptor saturation follows standard pharmacology. Adding a second GHRH agonist on top of near-saturating doses of the first does not proportionally increase GH output. The pituitary has a finite secretory reserve, and both compounds compete for the same downstream pathway. [2]

Additionally, sustained GHRH-receptor stimulation can downregulate GHRHR expression over time. A 2003 animal study in rats demonstrated reduced pituitary GHRHR mRNA after 14 days of continuous GHRH infusion compared to pulsatile dosing. [8] Whether that translates directly to humans using once-daily injections is unknown, but the signal warrants caution when stacking two GHRH agonists simultaneously.

When a Stack Might Make Sense

Some practitioners rotate sermorelin and tesamorelin rather than combining them. The rationale: tesamorelin's longer half-life and stronger receptor affinity provide more potent VAT reduction, while sermorelin's shorter pulse may reduce the risk of receptor downregulation during cycling. This is a clinical framework, not RCT-validated practice.

A reasonable rotation protocol used in some compounding-pharmacy-based practices looks like this:

• Phase 1 (weeks 1-12): Tesamorelin 2 mg subcutaneous nightly for VAT reduction.
• Washout (weeks 13-14): Both agents held to allow receptor resensitization.
• Phase 2 (weeks 15-26): Sermorelin 300-500 mcg subcutaneous nightly for ongoing GH pulse support.
• Re-evaluation at week 26: IGF-1, fasting glucose, DEXA or waist circumference to guide the next cycle.

This rotation framework is not FDA-endorsed and has no controlled trial data. Its use requires physician oversight, baseline labs, and informed consent about the off-label nature.

Choosing Monotherapy: When to Pick Tesamorelin

Tesamorelin wins on evidence whenever visceral fat is the primary target, the patient has HIV-associated lipodystrophy, or the prescriber needs a defensible regulatory basis for the prescription. The FDA label covers 2 mg daily subcutaneous injection in HIV-positive adults with lipodystrophy. [3]

Body Composition Goals

For patients whose primary complaint is central adiposity regardless of HIV status, tesamorelin's 15% VAT reduction over 26 weeks is a concrete, imaging-confirmed outcome. [4] Sermorelin has no comparable published VAT data.

IGF-1 Normalization

In a 2014 analysis of the Egrifta SV extension data, 67% of tesamorelin-treated patients achieved IGF-1 levels within the age-adjusted normal range at 52 weeks, compared with 18% in the placebo group. [5] That normalization rate gives prescribers a measurable biomarker to track.

Insurance Coverage

Tesamorelin carries approved ICD-10 indications tied to HIV lipodystrophy. Sermorelin, being compounded and off-label, is virtually never covered by commercial insurance. Cost matters for adherence: Egrifta SV list price is approximately $4,000 per month without manufacturer assistance programs, though patient assistance programs may reduce out-of-pocket cost significantly for qualifying patients.

Choosing Monotherapy: When to Pick Sermorelin

Sermorelin remains a reasonable choice for physicians managing adult patients who want physiologic GH support, cannot afford or do not qualify for tesamorelin, or prefer a compounded peptide with a long clinical history.

Cost and Accessibility

Compounded sermorelin typically costs $150-300 per month, making it far more accessible than branded tesamorelin for cash-pay patients. The compounding must comply with USP 797 sterility standards and ideally involve an FDA-registered 503B outsourcing facility to reduce quality-control risk. [9]

Sleep and Recovery Applications

Nightly dosing of sermorelin aligns with the body's largest natural GH pulse, which occurs during slow-wave sleep. A 2000 study in the European Journal of Endocrinology (N=40) found that subcutaneous GHRH administration 45 minutes before sleep onset augmented the nocturnal GH peak by approximately 40% in healthy older adults. [10] Tesamorelin has not been specifically studied in this sleep-timing context.

Milder IGF-1 Elevation

Patients with borderline-elevated IGF-1 at baseline, or those concerned about the theoretical long-term implications of sustained IGF-1 elevation, may prefer sermorelin's generally smaller IGF-1 increment. This is a clinical nuance, not a proven advantage, and IGF-1 should be monitored quarterly with either agent.

Dosing Protocols

Tesamorelin Dosing

The FDA-approved dose is 2 mg subcutaneous once daily, injected into the abdomen. Injection sites should be rotated. The labeling specifies administration in HIV-positive adults; use in other populations is off-label. [3]

Tesamorelin should be reconstituted with sterile water per the package insert. Reconstituted solution is stable for 24 hours under refrigeration. IGF-1 should be measured at baseline and at 6 and 12 weeks to confirm a therapeutic response and to screen for excess GH activity.

Sermorelin Dosing

Compounded sermorelin is typically prescribed at 200-500 mcg subcutaneous nightly, 5-6 nights per week, timed 30-60 minutes before sleep and 2-3 hours after the last meal to avoid blunting the GH response from insulin competition. [7] Some protocols use five-days-on, two-days-off cycling to limit receptor downregulation, though the evidence for this specific interval is observational.

Doses above 500 mcg nightly have not demonstrated meaningfully greater IGF-1 elevation in published literature and increase injection site reaction risk.

Monitoring for Both Agents

Regardless of which agent or protocol is used, the following lab schedule represents standard-of-care practice based on Endocrine Society guidance for GH axis monitoring: [6]

• Baseline: IGF-1, fasting glucose, HbA1c, lipid panel, DEXA or waist circumference.
• Week 6-8: IGF-1, fasting glucose.
• Week 12-16: IGF-1, fasting glucose, HbA1c.
• Week 26: Full metabolic panel, IGF-1, repeat DEXA or imaging.
• Ongoing: IGF-1 every 6 months; annual fasting glucose and HbA1c.

If IGF-1 exceeds the age-adjusted upper limit of normal on two consecutive readings, the dose should be reduced or the agent held pending physician review.

Safety Considerations

Shared Risks

Both agents carry a risk of fluid retention (edema, arthralgia, carpal tunnel syndrome), consistent with any GH-stimulating compound. The tesamorelin phase III data showed peripheral edema in approximately 6% of treated patients versus 2% placebo. [4]

Glucose metabolism deserves attention. Growth hormone antagonizes insulin action. The LIPO-010 trial showed no significant HbA1c change at 26 weeks, but patients with pre-existing insulin resistance or type 2 diabetes should have more frequent glucose monitoring. The FDA label for tesamorelin includes a warning about glucose intolerance. [3]

Contraindications

Tesamorelin is contraindicated in pregnancy, active malignancy, and disruption of the hypothalamic-pituitary axis (for example, pituitary tumor or post-cranial irradiation). [3] Sermorelin shares these contraindications by mechanism even though it lacks an active FDA label.

Patients with active cancer should not use GHRH analogues. IGF-1 is a mitogenic signaling molecule, and GH axis stimulation in the setting of malignancy is not supported by any trial data and carries theoretical risk of tumor proliferation. [11]

Drug Interactions

Glucocorticoids blunt the GH response to GHRH by suppressing pituitary somatotroph sensitivity. Patients on chronic corticosteroid therapy may see an attenuated IGF-1 rise with either peptide. [6] Thyroid hormone status also matters: hypothyroidism reduces GH secretion, so undertreated hypothyroidism should be corrected before starting either agent.

The Stack Decision: A Practical Framework

No randomized trial justifies combining sermorelin and tesamorelin simultaneously. Given receptor overlap, additive cost, and the theoretical downregulation risk, simultaneous stacking offers uncertain upside with measurable downside.

The cleaner clinical logic runs as follows:

1. Primary goal is VAT reduction with strong evidence support. Use tesamorelin 2 mg nightly. Confirm VAT change by CT or MRI at 26 weeks.
2. Primary goal is nocturnal GH pulse support, cost is a constraint, or the patient lacks HIV-lipodystrophy criteria. Use compounded sermorelin 300 mcg nightly from a USP-797-compliant pharmacy.
3. Long-term GH axis support with periodic cycling. Consider alternating tesamorelin (12-week blocks) with sermorelin (12-week blocks) separated by 2-week washouts. Monitor IGF-1 throughout. Treat this as an off-label protocol requiring full informed consent.
4. Simultaneous combination. Reserve for physician-supervised investigational contexts only. No routine use is supported by current evidence.

The Endocrine Society states: "Patients with GH deficiency may experience improvements in body composition, exercise capacity, skeletal integrity, and quality of life with GH therapy," but emphasizes that "treatment should be individualized and monitored carefully." [6] That principle applies equally to GHRH analogue use.

What Practitioners and Patients Should Know Before Starting

Tesamorelin is a prescription drug dispensed through licensed pharmacies. Sermorelin, in compounded form, requires a physician's prescription and a compliant compounding pharmacy. Neither peptide should be purchased from research-chemical vendors, where quality and sterility are unverified. The FDA has issued warning letters to several such vendors. [9]

Before starting either agent, a prescribing clinician should review thyroid function, fasting glucose, and a baseline IGF-1. Patients over 60 or those with a personal or family history of colon polyps warrant a colonoscopy discussion, given GH axis stimulation's potential effects on cell proliferation, though direct evidence of peptide-induced polyp risk is limited. [11]

At 26 weeks, CT or MRI measurement of visceral fat is the most objective outcome metric for tesamorelin. For sermorelin used in a general GH-support context, IGF-1 normalization and patient-reported sleep quality, recovery, and body composition are the practical endpoints.

The mean IGF-1 increase seen with tesamorelin 2 mg daily in phase III trials was approximately 94 ng/mL above placebo baseline at 26 weeks. [4] A clinician seeing less than a 30 ng/mL IGF-1 rise after 8 weeks of tesamorelin should investigate adherence, injection technique, and thyroid status before escalating dose or adding a second agent.